Medical Director, Clinical Cancer Programs for the Ireland Cancer Center and University Hospitals Case Medical Center
Education:
M.B.A. - 1996 - Weatherhead School of Management, Case Western Reserve University
M.D. - 1980 - Tufts University School of Medicine, Boston, MA - Medicine
B.A. - 1976 - Brandeis University, Waltham, MA
Professional Training:
1980-1983 - Internship and Residency in Internal Medicine,
Boston Veterans Administration Medical Center
1983-1984 - Clinical Fellowship in Hematology/Oncology
Boston Veterans Administration Medical Center
1984-1985 - Clinical and Research Fellowship in Blood Banking
and Immunohematology University of Massachusetts Medical Center
1985-1986 - Clinical Fellowship in Hematology/Oncology University of Massachusetts Medical Center
Certification:
1983 - Internal Medicine
1985 - Medical Oncology
1986 - Hematology
Board Eligibility:
Blood Banking
CLINICAL RESEARCH (2000-2002):
Principal Investigator for the Following Trials:
AGRN 1599 - CDDP/GEM +/- AG3340 in NSCLC
CWRU 1597 - 9-AC in NSCLC
GLAX 1500 - IV vs. PO Navelbine in Elderly Patients
LANP 1598 - Taxol/CBDCA/RT for NSCLC
SKF 1598 - Oral vs. IV Topotecan in SCLC
BNC 1501 - Taxotere + COX-2 Inhibitors in NSCLC
CWRU 1599 - Randomized Rebeccamycin in NSCLC
CLINICAL RESEARCH (2000-2002):
Principal Investigator for the Following Trials:
ORTH 1599 - Procrit vs. No Procrit in NSCLC
SCH 1501 - Temozol in Brain Mets from NSCLC
SKF 1501 - TOPO+CDDP vs. VP16+CDDP for SCLC
Publications:
Articles:
1. Dowlati A, Levitan N, Remick S. Evaluation of Interleukin-6 in bronchoalveolar
lavage fluid and serum of patients with lung cancer. J Lab Clin Med 134:405-9, 1999.
2. Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski L, Beyth R, Rimm A. Rates of thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using medicare claims data. Medicine 78:285-91, 1999.
3. Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick S,
Chang A, Johnson D. A multi-institutional trial of paclitaxel, cisplatin and etoposide
with concurrent radiation and filgrastim support for localized stage small cell lung
carcinoma. J Clin Onc 18:1102-9, 2000.
4. Levitan N. Developing a network of community-based delivery sites. Oncology Issues 15:14-19, 2000.
5. Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Onc 18:2095-2103, 2000.
6. Chak A, Levitan N. Endosonographic assessment of multimodality therapy predicts
survival in esophageal cancer patients. Cancer 88:1788-95, 2000.
7. Dowlati A, Crosby L, Remick S, Makkar V, Levitan N. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer – the use of complete response rate as the primary endpoint in phase II trials. Lung Cancer 32:155-62, 2001.
8. Dowlati A, Levitan N, Gordon N, Hoppel CL, Gosky DM, Remick SC, Ingalls ST, Berger SJ, Berger NA. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 47:141-148, 2001.
9. Willis J, Cooper G, Isenberg G, Sivak M, Levitan N, Clayman J, Chak A. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 55:655-61, 2002.
10. Dowlati A, Levitan N. Combination chemotherapy with topotecan for non-small cell
lung cancer. Lung Cancer 41:S23-6.
11. Belani C, Adak S, Aisner S, Stella P, Levitan N, Johnson D. Docetaxel for malignant mesothelioma: Phase II study of the Eastern Co-Operative Oncology Group. J Clin Onc (In Press).
Abstracts:
1. Levitan N, Dowlati A, Craffey M, Remick S, Shina D, Devore R, Jett J, Chang A,
Johnson D. A multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation and filgrastim support for limited-stage small cell lung carcinoma (LS-SCLC). Proceedings of ASCO 18:1809, 1999.
2. Shepherd F, Ramlau R, Mattson K, Gressot L, O’Rourke M, Vincent M, Burkes R,
Levitan N, Bergman B, Kraszko P, Baez L, Lynch T, Rudd R, Berille J, Kim Y,
Coughlin S, Gralla R. Randomized study of taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proceedings of ASCO 18:1784, 1999.
3. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH. Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595). Proceedings of ASCO 18:1829, 1999.
4. Dancey J, Shepherd F, Ramlau R, Mattson K, Gressof L, O’Rourke M, Vincent M, Burkes R, Levitan N, Bergman B, Krasko P, Baez L, Rudd R, Kim Y, Coughlin S, Soussan-Lazard K, Gralla R. Quality of life assessment in a randomized study of taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proceedings of ASCO 18: 1896, 1999.
5. Remick SC, Dowlati A, Robertson K, Spiro T, Connell C, Levitan N. Phase I pharmacokinetic study of single dose intravenous combretastatin A4 prodrug (CA4P) in patients with advanced cancer. Cancer Invest 18(Suppl 1): 105-6, 1999.
6. Remick SC, Dowlati A, Lewin J, Robertson K, Makkar V, Overmoyer B, Spiro T,
Connell C, Levitan N, Buchter C, Stambler B, Taylor A, and Stratford M. A phase I
pharmacokinetic (PK) study of single dose intravenous (IV) combretastatin A4
Prodrug (CA4P) in patients (pts) with advanced cancer. Proceedings of ASCO 19:697, 2000
7. Sandler A, Declerck L, Wagner H, Levitan N, DeVore R, Levitt M, Johnson D. A
Phase II study of cisplatin plus etoposide plus paclitaxel and concurrent
radiation therapy for previously untreated limited stage small cell lung cancer
(E2596): An Eastern Cooperative Oncology Group Trial. Proceedings of ASCO
19:1920, 2000.
8. Levitan N, Dowlati A, Hoppel C, Ingalis S, Inverso J, Silver B, Cunningham J, Berger N, Remick S. Phase II and Pharmacokinetic Trial of 9-aminocamptothecin colloidal dispersion 120-hour continuous intravenous infusion in advanced non-small cell lung cancer. Proceedings of ASCO 19:1963, 2000.
Department of Medicine|
11100 Euclid Avenue| Cleveland, Ohio 44106
